The U.S. Supreme Court refuses to hear an appeal from W.L. Gore & Assoc. in a patent war with C.R. Bard over stent graft technology.

C.R. Bard logo
W.L. Gore & Associates logo
The U.S. Supreme Court dashed the last hopes of W.L. Gore & Assoc. its long-running patent war with C.R. Bard (NYSE:BCR) over vascular graft technology.

Last October Gore asked the Supremes to consider its appeal of a $186 million patent loss to Bard.

Today the high court denied that bid, whereupon Bard promptly filed a motion to compel payment in the U.S. District Court for Arizona, according to a regulatory filing.